Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Marcus Caine

Marcus Caine

Biocompatibles UK Ltd, UK

Title: In vitro characterisation method for comparative evaluation of drug loaded embolic distal perfusion

Biography

Biography: Marcus Caine

Abstract

In vitro biomimetic models have become increasingly utilised in the evaluation of medical devices over the last 30 years. Application in the field of Interventional Oncology for modelling purposes has been limited by the complexity of recreating biological vascular systems. Interventional Oncology and specifically embolisation, varies significantly in terms of its administration methodology. The specific process of blocking the primary blood supply to a hyper-vascularised tumour is anything but simple in terms of reproducibility and translation between patients, clinics and devices. Flow properties of drug-loaded embolic microspheres have been shown to influence the distribution, contact diffusion and spatial drug elution kinetics within tumours [1]. Moreover, variations in the administration style of the physician have been shown to play a significant part in the intra-tumoural distribution [2]. To model the unique flow properties of various embolic products, novel in vitro microfluidic test systems have been developed. Through compartmentalised recreations of clinical conditions, it becomes possible to predict and evaluate relevant flow properties prior to use in vivo. This presentation will analyse the effect of channel flow rate (Reynold’s number) and embolic size of doxorubicin loaded DC Bead™ 70-150µm and 100-300µm within in vitro flow channels of sizes representative of distal hepatic microvasculature. The effect of whole bead distribution is considered as a vehicle for distal drug distribution utilising clinically representative injection volumes for modelling bolus effects. A significantly higher dose (p=0.017) is observed in smaller flow channels with 70-150µm vs. 100-300µm trending with increased flow rates.